We show that the KRAS degrader efficiently induces endogenous KRAS degradation in vitro and in vivo and specifically inhibits mutant KRAS tumours without affecting cells with only KRASWT, whereas the pan-RAS degraders inhibit all type of cells, regardless of the RAS isoform mutation. Here, KRAS is linked to neoplasm.